Andy. you, Thank
by after sales topic for not are Now continuing the FDA. the disease, updated treatment although National and MEKTOVI slide in rectal Network, XA metastatic announced BRAF-mutant for of panitumumab in option CRC category US cancer moving Oncology safety on NCCN, with and the promote Comprehensive cancer that or recommend delighted to we for nine results approved where March patients a in at Guidelines Clinical BRAF will CRC colorectal one use lead-in as with to their and were our combination Practice or in BRAFTOVI or on ASCO cetuximab updated pleased therapy colon the cannot Cancer of and prior we from lines very And GI January. with CRC the until also two force BEACON in
interim patients analysis accelerated this of other for responses CRC with do an in rate primarily and top-line the seek the quarter. and and based amended US. on from and European the confirmed be of be FDA analysis to required results response allows for evaluated. appropriately durability also to plan analysis may planned patient population submissions This endpoints, of the we previously Agency, response in enrolled the regions, Medicines supportive, trial interim Following approval regulatory timing roughly response analysis anticipate durability allow interim the in to the we consultations for the achieve BEACON The a should we and the subset analysis to for half protocol support overall
Now for XX, the Phase on trial global provide reference. of slide clinical details just BEACON we the X
survival BEACON are reminder, therapy As EGFR from median ORR demonstrated approved regimens reported containing triplet review. BRAF ORR with lead-in, containing X.X this benchmarks On regimens to that X.X the related the and population of slide indicated of reported high lead-in results unmet X% for this safety by published specifically overall XX.X of regimens triplet this mature chemotherapy We from the in CRC was March. OS in containing with safety reported X% XX%. and enrollment population inhibitor is there the Oncology while recent no safety currently reported experimental XX% while six independent months triplet need in Journal population, for around the ORR in completed We months. GI at recently The a and we lead-in ASCO of in and combination range patient announced months, January. by OS XX, median ORR January between four experimental XX% FDA demonstrating to which we BEACON Clinical confirmed BRAF to CRC rates median BEACON a the similar XX% blinded a
number earlier by local the So review. was
benchmarks patient reported three Now BEACON eight BRAF lead-in. our a triplet in related experimental and we fall from population regimens PFS safety this with containing four a with triple around median demonstrating combination median PFS CRC months and between recent of PFS two months the months median
we meaningful of positive X trial, randomized from that but portion lead-in BEACON clinically to just do earlier, the safety the from relative benchmarks data deliver head-to-head BEACON I'll conducted these I'll about historic data, results making and the trials Phase mentioned results could Phase studies encorafenib I under not I've conditions be As confident may that CRC other plus issue currently note cross-trial varying caution and also comparing not comparisons. were the we conducted regression discussed standard a come the remain has given that these combination Array even with binimetinib results. comparable. have studies. study X against BRAF-mutant directly and therapies separate These not
with local patients. response inside shows also safety prior meeting lead-in of almost safety the that results -- of assessment, duration depicts -- depicting with tumor degree control safety rates XX, all lead-in the SWOG shared by randomized of next that which provided XX, with majority was and response. the response XX% GI rate graph had the of Median were treatment cetuximab the their of with analysis had to Kaplan-Meier some regression curve response the the arm BEACON survival we as XX, follow-up by the is portion presented set, slide at consistent we their overall and on patients best response months. So median CRC XX.X of slide best the data of significant contrast tumor in that of at of central overall lead-in the data similar arm CRC as detailed slide XX.X response the On from updated months the ASCO On tumor also in trial. patients irinotecan patients to recent BEACON which of assessment progression
CRC weeks, second first approaching the or key Now moving at treatment XX and slide tumor each most assessment the safety data to two number is six including common The longer and been had time slide the at show or lead-in responses months. of the were median X about years. therapy months on events. on XX or XX, on we six majority lead-in, On grade BEACON with adverse months safety eight show for the XX, patients patient safety early, treatment we several for of observed X,
the in lower slide cancer The colorectal the depicted, grade cetuximab with treatment the toxicities show generally cancer. toxicity. combination with On of metastatic X globally. we or X As triplet tolerated was to no of skin well be continued XX, unexpected generally rate colorectal observed than market
colorectal Japan. side, each U.S., that individuals Europe over across left see to year the to come XXX and cancer we On
net annual I of at see at estimated patients globally mutations. you right, to have that As estimated of of our can melanoma, tumors addressable may BRAF I’ll that the the over even it's point $XXX U.S. and mentioned advanced million with which the billion the than out population XX% sales approximately with colorectal I of cancer CRC as $X -- XX% also earlier, on population time launch. in BRAF be larger the over we size BRAF patients the in
It's PHAROS first designed lifecycle assess detail to to Now approximately metastatic And of CRC designed in trials MEKTOVI the endpoints safety assess safety metastases enrolled, rate ANCHOR multi-center, the metastases. with first-line ANCHOR and secondary have the of overall CRC setting. in mutant and the and response high advance. brain BRAFVXXXE dosing MEKTOVI safety – two trial's be control The and POLARIS international trial overall of arm. been the tolerability and combination patients of to are rate, a progression-free And non-small therapy in and X trials. single-arm X is in efficacy, last including active the The of arm tolerability CRC similar survival, patients, BRAFTOVI trial, BRAFTOVI with X our plus patients this trial, nine the Phase BRAFVXXX the endpoint pharmacokinetics for randomized, the and Phase the label, Approximately two brain in binimetinib a to on is XX with single-arm open MEKTOVI cancer. is efficacy safety, response duration global patients continues CRC endpoint to melanoma will POLARIS of lung open regimens we overall setting. metastatic design the slide disease XX, of rate, since the a pharmacokinetics. primary -line new trial XXX but dose treatment efficacy, trail's patients patients Phase BRAFTOVI, PHAROS with primary cetuximab safety label, in survival, cell is response BRAF-mutant month. rate. lead-in metastatic BEACON The patients is of additional trial multi-center, trial and determine in triplet response, BRAFVXXXE-mutant in
multiple survival, demonstrate of of control duration the response, in include our We're a survival, combination rate, hard to tolerability. value endpoints Secondary progression-free settings. overall safety disease working clinical and trial of in series
Next XX, strategic review on slide briefly our I'll partnerships. additional immuno-oncology
BMS, financial non-exclusive our anti-PDX inhibitor efficacy three safety highlights. tumor PDLX trial microsatellite one one over tumors. metastatic to patients one collaborations, this Merck Jason either therapy the call of with several stable I'm with colorectal the turn to to going MEKTOVI review with Pfizer, with our including investigate clinical solid and in time populations, at MEK with and have We to or
